Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and Opioid Use Relapse in Veterans
NCT04360681Phase 2Completed
- Sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lofexidine in opioid use disorder (OUD), post-traumatic stress disorder (PTSD), sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance. Started Mar 2021; status: completed.
02
Drugs
lofexidine
03
Conditions
opioid use disorder (OUD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04360681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360681.